Navigation Links
Lung cancer cells activate inflammation to induce metastasis
Date:12/31/2008

A research team from the University of California, San Diego School of Medicine has identified a protein produced by cancerous lung epithelial cells that enhances metastasis by stimulating the activity of inflammatory cells. Their findings, to be published in the January 1 issue of the journal Nature, explain how advanced cancer cells usurp components of the host innate immune system to generate an inflammatory microenvironment hospitable for the metastatic spread of lung cancer. The discovery could lead to a therapy to limit metastasis of this most common lethal form of cancer.

The scientists headed by Michael Karin, Ph.D., UC San Diego Distinguished Professor of Pharmacology and Pathology, who has been investigating the effects of inflammation on cancer development and progression used a straightforward biochemical approach to identify proteins produced by metastatic cancer cells that are responsible for generation of an inflammatory microenvironment that supports the growth of metastases. Focusing on macrophages, white blood cells that are key players in the immune response to foreign invaders as well as in cancer growth and progression, they screened for factors produced by metastatic cancer cells in mice that could stimulate the activity of this inflammatory cell type.

Among the mouse cell lines screened, a highly metastatic cell line called Lewis lung carcinoma (LLC) showed particularly potent activation of macrophages. Furthermore, macrophage activation was mediated by a secreted protein. Biochemical purification of proteins secreted by LLC cells resulted in identification of an extracellular matrix protein called versican as the major macrophage activator and metastasis enhancing factor. Versican is also found in very low amounts in normal human lung epithelial cells, but is upregulated in human lung cancer, where a very large amount of this protein is found, especially in aggressive tumors.

The scientists found that versican strongly enhances LLC metastatic growth by activating receptors that lead to production of cytokines signaling proteins that regulate the immune system. One of these receptors, TLR2, and a cytokine, TNFα, were found to be required for LLC metastasis. However, the normal function of TLR2 and TNF is in host defense-innate immunity to microbial infections. According to Karin, these findings are relevant, not just to the mouse model, but also to human lung cancer the most common cause of cancer-related deaths worldwide. The major cause of lung cancer is tobacco smoking.

"By usurping these elements of the host immune system, versican helps generate an inflammatory environment that spurs the growth and spread of metastatic cancer," said Karin. "If we can find a way to block the production of versican or its binding to TLR2, therapeutic intervention could be used to limit metastasis of lung cancer."


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Why prostate cancer patients fail hormone deprivation therapy
2. Few DNA repair genes maintain association with cancer in field synopsis
3. High Insulin May Boost Odds of Breast Cancer
4. Vitamins Fail to Prevent Cancer: Study
5. Errors involving medications common in outpatient cancer treatment
6. Young blood fights cancer
7. Food Phosphates Might Spur Lung Cancer
8. Minimizing obesitys impact on ovarian cancer survival
9. RCOG.com and ProstRcision.com Increase Online Presence for Cancer Information
10. Lung Cancer: Still the Biggest Cancer Killer, by Far
11. Cancer drug effectively treats transplant rejections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... selected to renovate and improve the Ramsey County Medical Examiners Facility located in ... Hospital, the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... ... 21, 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush ... Society of Sports Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine ... Canada. This prestigious award is given annually to honor those who have made a ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ChenMed ... MD, has joined JenCare Senior Medical Center as Richmond Chief Medical Officer. ... School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology: